Type II Alveolar Redox Control in Fibrogenesis and Resolution
Type II Alveolar Redox Control in Fibrogenesis and Resolution
批准号:
10063554
负责人:
Ana Lucia Mora
金额:
$9.93万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-12-01 至 2021-01-31
关键词:
AddressAgeAgingAlveolarCell AgingCell LineCellular StressChronicCicatrixCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic GMPCyclic GMP-Dependent Protein KinasesDataDiseaseElderlyEnzymesEpithelial CellsEtiologyFibrosisFlavoproteinsGenesGrantGrowth FactorHeartHemeHeme IronImpaired wound healingImpairmentIndividualInjuryKidneyKnockout MiceLeadLinkLungLung diseasesMediatingMitochondriaModelingMolecularMusMuscle relaxation phaseMutationNADHNatural regenerationNatureNitric OxideOxidation-ReductionOxidative StressOxidesPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhenotypePredispositionPrevalenceProcessProtein IsoformsPulmonary FibrosisReactive Oxygen SpeciesRegulationResolutionRoleSecond Messenger SystemsSignal PathwaySignal TransductionSoluble Guanylate CyclaseStressSyndromeTelomeraseTestingTimeTissuesTransforming Growth Factor betaTreatment EfficacyType II Epithelial Receptor CellUp-RegulationVascular Smooth MuscleWorkage relatedalveolar epitheliumalveolar type II cellbasechronic woundcytochrome b5 reductasefibrogenesishealthspanidiopathic pulmonary fibrosisinterstitialknock-downlung developmentmitochondrial dysfunctionmouse modelnovelnovel therapeutic interventionoxidationresilienceresponsesenescencetheoriestherapeutic targettissue repairwound healing
中文摘要
摘要:特发性肺纤维化(IPF)是一种慢性高致死性肺部疾病,其特征是
肺过度瘢痕化,其患病率在老年人中增加。接受度最高的
IPF发病机制的理论是肺泡上皮II型细胞(AECII)的损伤和活化,
过度和慢性伤口愈合反应,由生长因子如TGF-β 1介导。氧化
应激被认为是组织修复过程的关键调节因子,但氧化还原信号通路在
IPF的病理生物学机制在很大程度上仍然未知。一种依赖于NADH的氧化还原酶,
有助于压力保护并与健康和衰老相关的是Cyb 5 R3(Cyb 5 R3)。Cyb5R3
还原血红素铁(Fe 3 +→ Fe 2+),这是活性氧的主要目标。我们的初步数据显示,
IPF肺具有Cyb 5 R3的低表达。使用一种新的Cyb 5 R3条件性缺陷小鼠模型,
本实验室培养的肺泡Ⅱ型细胞中,我们发现:1)Cyb 5 R3在肺泡Ⅱ型细胞中的表达和活性,
对于防止肺纤维化至关重要,2)Cyb 5 R3负调节TGF-β 1-β 2的表达。
依赖性促纤维化和衰老基因,和3)Cyb 5 R3抑制TGF-β 1靶基因的表达
由两条途径介导,一条是sGC的血红素还原,另一条是下游cGMP-PKG的激活
第二,通过控制线粒体功能和激活cAMP-PKA。这些
观察结果表明,Cyb 5 R3缺陷会促进AECII线粒体的改变
通过sGC依赖性和非依赖性途径增强TGF-β信号传导的功能和氧化还原状态
降低抗纤维化的弹性:目的1。为了验证肺泡上皮细胞中Cyb 5 R3
通过抑制TGF-β信号传递来保护肺纤维化的发展。目标2.
确定AECII Cyb 5 R3表达缺失是否赋予慢性sGC刺激剂和/或sGC激活剂效力
治疗小鼠肺纤维化。这些目标的实现将使我们更好地了解
Cyb 5 R3在创伤愈合过程中的作用以及与年龄相关的损伤修复和纤维化恢复机制。
英文摘要
Abstract: Idiopathic Pulmonary Fibrosis (IPF) is a chronic and highly lethal lung disease characterized by
excessive scarring of the lung and whose prevalence is increased in older individuals. The most accepted
theory in the pathogenesis of IPF is the injury and activation of alveolar epithelial type II cells (AECII) triggering
excessive and chronic wound-healing responses, mediated by growth factors such as TGF-b1. Oxidative
stress is recognized as key regulator of the tissue repair process, but the role of redox signaling pathways in
the mechanistic pathobiology of IPF remains largely unknown. One NADH-dependent redox enzyme that
contributes to stress protection and associates with healthspan and aging is Cyb5R3 (Cyb5R3). Cyb5R3
reduces heme iron (Fe3+→Fe2+), a major target of reactive oxygen species. Our preliminary data suggest that
IPF lungs have low expression of Cyb5R3. Using a novel mouse model of conditional deficiency of Cyb5R3 in
alveolar type II cells developed in our labs, we have found that 1) expression and activity of Cyb5R3 in AECII
are critical for protection against lung fibrosis, 2) Cyb5R3 negatively regulates the expression of TGF-b1-
dependent profibrotic and senescence genes, and 3) Cyb5R3 inhibition of expression of TGF-b1 target genes
is mediated by two pathways, one the heme reduction of sGC and downstream activation of cGMP-PKG
signaling pathway, and second, by control of mitochondrial function and activation of cAMP-PKA. These
observations have led to the hypothesis that Cyb5R3 deficiency promotes alteration of the AECII mitochondrial
function and redox state that enhances the TGF-b signaling via sGC-dependent and –independent pathways
decreasing the resilience against fibrosis: Aim 1. To test the hypothesis that Cyb5R3 in alveolar epithelial cells
confers protection against the development of lung fibrosis through suppression of TGF-b signaling. Aim 2.
Establish if loss of AECII Cyb5R3 expression confers efficacy to chronic sGC stimulator and/or sGC activator
therapy in mice with lung fibrosis. Completion of these aims will enhance our understanding of the role of
Cyb5R3 in the wound healing process and age-related mechanisms of resilience to disrepair and fibrosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Type II Alveolar Redox Control in Fibrogenesis and Resolution
-
批准号:10392756
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2020
-
负责人:Ana Lucia Mora
-
依托单位:
Type II Alveolar Redox Control in Fibrogenesis and Resolution
-
批准号:10539344
-
项目类别:
-
资助金额:$49.05万
-
财政年份:2020
-
负责人:Ana Lucia Mora
-
依托单位:
Type II Alveolar Redox Control in Fibrogenesis and Resolution
-
批准号:10307623
-
项目类别:
-
资助金额:$49.19万
-
财政年份:2020
-
负责人:Ana Lucia Mora
-
依托单位:
Signaling mechanisms by which mitochondria regulates fibrosis in the lung
-
批准号:9233787
-
项目类别:
-
资助金额:$43.48万
-
财政年份:2016
-
负责人:Ana Lucia Mora
-
依托单位:
Signaling mechanisms by which mitochondria regulates fibrosis in the lung
-
批准号:9079520
-
项目类别:
-
资助金额:$43.48万
-
财政年份:2016
-
负责人:Ana Lucia Mora
-
依托单位:
Aging and Lung Disease: Clinical Impact and Cellular and Molecular Pathways
-
批准号:8785180
-
项目类别:
-
资助金额:$2.57万
-
财政年份:2014
-
负责人:Ana Lucia Mora
-
依托单位:
Immunobiology of Lung Fibrosis
-
批准号:6732687
-
项目类别:
-
资助金额:$12.57万
-
财政年份:2003
-
负责人:Ana Lucia Mora
-
依托单位:
Immunobiology of Lung Fibrosis
-
批准号:6602540
-
项目类别:
-
资助金额:$12.33万
-
财政年份:2003
-
负责人:Ana Lucia Mora
-
依托单位:
Immunobiology of Lung Fibrosis
-
批准号:6881060
-
项目类别:
-
资助金额:$12.82万
-
财政年份:2003
-
负责人:Ana Lucia Mora
-
依托单位:
Immunobiology of Lung Fibrosis
-
批准号:7214063
-
项目类别:
-
资助金额:$13.33万
-
财政年份:2003
-
负责人:Ana Lucia Mora
-
依托单位:
Immunobiology of Lung Fibrosis
-
批准号:7033855
-
项目类别:
-
资助金额:$13.07万
-
财政年份:2003
-
负责人:Ana Lucia Mora
-
依托单位:
Preclinical Assessment Core
-
批准号:9322486
-
项目类别:
-
资助金额:$38.9万
-
财政年份:--
-
负责人:Ana Lucia Mora
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: